NO20052860L - Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme - Google Patents

Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme

Info

Publication number
NO20052860L
NO20052860L NO20052860A NO20052860A NO20052860L NO 20052860 L NO20052860 L NO 20052860L NO 20052860 A NO20052860 A NO 20052860A NO 20052860 A NO20052860 A NO 20052860A NO 20052860 L NO20052860 L NO 20052860L
Authority
NO
Norway
Prior art keywords
pellet
acrylic polymer
water
cores
tamsulosin
Prior art date
Application number
NO20052860A
Other languages
English (en)
Other versions
NO20052860D0 (no
Inventor
Johannes Jan Platteeuw
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23131212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052860(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of NO20052860D0 publication Critical patent/NO20052860D0/no
Publication of NO20052860L publication Critical patent/NO20052860L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen omhandler en farmasøytisk doseringsform omfattende flere pelletter, hvori hver pellett omfatter: a) en pellettkjerne med en diameter innefor området 0,3-0,9 mm og omfattende et tamsulosinhydroklorid, mikrokrystallisk cellulose, en farmasøytisk akseptabel permeabel akrylpolymer og vann, og b) et ytre beleggslag som omgir kjernen omfattende en farmasøytisk akseptabel akrylpolymer med syremotstand, hvori massen til det ytre laget, beregnet basert på tørre pellettkjerner, er innenfor området 2,5 til 15 %, og hvori de fleste pellettene utviser en oppløsningsfrigivelsesprofil i simulert magevæske ved anvendelse av Ph. Eur. Basketmetoden ved 100 rpm som inkluderer frigivelse av mindre enn 10 % av tamsulosinen de første to timene, samt en fremgangsmåte omfattende: a) å granulere en blanding av tamsulosin hydroklorid, mikrokrystallisk cellulose, akrylpolymer, vann og alternativt ytterligere ingredienser for å danne våte pellettkjerner, b) å tørke de våte pellettkjernene til en restmengde med vann på 2-10 %, c) å sile de tørkede pellettkjernene for å oppnå en fraksjon innenfor størrelsesområdet 0,3-0,9 mm, d) å belegge de silte tørkete pellettkjernene med en beleggssammensetning omfattende en vannløselig akrylpolymer med syremotstand, og c) å tørke den belagte pelletten, hvori belegningstrinnet d) er tilstrekkelig for å gi en tørket belagt pellett innenfor 2,515 masseprosent av beleggssammensetningen, beregnet basert på den tørre pellettkjernen, samt dens anvendelse som et medikament.
NO20052860A 2002-11-14 2005-06-13 Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme NO20052860L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/293,940 US7018658B2 (en) 2002-11-14 2002-11-14 Pharmaceutical pellets comprising tamsulosin
PCT/NL2002/000821 WO2004043449A1 (en) 2002-11-14 2002-12-12 Pharmaceutical pellets comprising tamsulosin and a process for making the same

Publications (2)

Publication Number Publication Date
NO20052860D0 NO20052860D0 (no) 2005-06-13
NO20052860L true NO20052860L (no) 2005-08-10

Family

ID=23131212

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052860A NO20052860L (no) 2002-11-14 2005-06-13 Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme

Country Status (23)

Country Link
US (1) US7018658B2 (no)
EP (1) EP1562573B1 (no)
JP (1) JP5405710B2 (no)
AT (2) ATE323478T1 (no)
AU (3) AU2002351451A1 (no)
BE (1) BE1015435A4 (no)
CA (1) CA2415840C (no)
CH (1) CH696419A5 (no)
CZ (1) CZ13341U1 (no)
DE (2) DE60210828T2 (no)
DK (2) DK1562573T3 (no)
ES (1) ES2257589T3 (no)
FI (1) FI5842U1 (no)
FR (1) FR2847166B1 (no)
GB (1) GB2395125B (no)
HU (1) HUP0500832A3 (no)
NL (1) NL1022151C2 (no)
NO (1) NO20052860L (no)
PL (1) PL206083B1 (no)
PT (1) PT1562573E (no)
SI (1) SI21394A2 (no)
WO (2) WO2004043449A1 (no)
ZA (1) ZA200503696B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04008100A (es) * 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US20060147531A1 (en) * 2003-07-01 2006-07-06 Mojca Segula Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
AU2003286415A1 (en) * 2003-12-03 2005-06-24 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
KR100615952B1 (ko) * 2004-05-27 2006-08-28 한국화학연구원 서방형 약물 전달 시스템
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
SI1618873T1 (sl) * 2004-07-14 2007-10-31 Siegfried Generics Int Ag Granulat za kontrolirano sproščanje tamsulozina, ki vsebuje alginat
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007017253A1 (de) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung eines benzolsulfonamids
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR100745515B1 (ko) * 2006-04-10 2007-08-02 주식회사 대웅제약 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법
WO2007131804A1 (en) 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
EP2047847A1 (en) * 2007-10-12 2009-04-15 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising tamsulosin
WO2009047312A1 (en) * 2007-10-12 2009-04-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising tamsulosin
EP2373297A1 (en) * 2008-12-09 2011-10-12 Synthon B.V. Tamsulosin pellets for fixed dose combination
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
EP2838512B1 (en) 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
KR20160021095A (ko) 2013-06-21 2016-02-24 욱크하르트 리미티드 탐술로신 또는 이의 염의 약학 조성물
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
CZ2015225A3 (cs) * 2015-03-30 2016-10-12 Zentiva, K.S. Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
CN105287395A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
BR112018069852A2 (pt) 2016-03-31 2019-01-29 Hanmi Pharm Ind Co Ltd formulação compósita de cápsula e método para preparar a formulação compósita de cápsula
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
US20250241911A1 (en) 2021-10-25 2025-07-31 Farmalíder, S.A. Tadalafil oral suspension

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
JPS61100526A (ja) * 1984-10-22 1986-05-19 Kyowa Hakko Kogyo Co Ltd 持続性ドパミン経黒剤
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
JPH07316077A (ja) * 1994-05-20 1995-12-05 Sumitomo Pharmaceut Co Ltd 腸溶性コーティング用組成物
US6177430B1 (en) * 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
KR20020016944A (ko) * 1999-08-09 2002-03-06 오노다 마사요시 하부 요로증 치료용 의약 조성물
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
EP1207860B1 (en) * 1999-09-02 2007-10-24 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
US6368628B1 (en) 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
JP2005512997A (ja) * 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ タムスロシン錠
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin

Also Published As

Publication number Publication date
CA2415840A1 (en) 2004-05-14
AT6542U1 (de) 2003-12-29
GB2395125A (en) 2004-05-19
BE1015435A4 (nl) 2005-04-05
AU2003288083A1 (en) 2004-06-03
PL206083B1 (pl) 2010-06-30
JP2006508960A (ja) 2006-03-16
AU2002351451A1 (en) 2004-06-03
JP5405710B2 (ja) 2014-02-05
CZ13341U1 (cs) 2003-06-02
ZA200503696B (en) 2006-08-30
PL357856A1 (en) 2004-05-17
FR2847166A1 (fr) 2004-05-21
DE20219293U1 (de) 2003-06-05
DK200300005U3 (da) 2003-04-25
AU2003200059A1 (en) 2004-06-03
NL1022151C2 (nl) 2004-05-18
US7018658B2 (en) 2006-03-28
CH696419A5 (de) 2007-06-15
AU2003200059B2 (en) 2008-07-03
FR2847166B1 (fr) 2005-06-10
EP1562573B1 (en) 2006-04-19
US20040096502A1 (en) 2004-05-20
GB0229021D0 (en) 2003-01-15
DE60210828D1 (de) 2006-05-24
WO2004043449A1 (en) 2004-05-27
HUP0500832A2 (en) 2007-07-30
PT1562573E (pt) 2006-07-31
FI5842U1 (fi) 2003-07-03
ATE323478T1 (de) 2006-05-15
CA2415840C (en) 2008-11-18
SI21394A2 (sl) 2004-06-30
WO2004043448A1 (en) 2004-05-27
NO20052860D0 (no) 2005-06-13
GB2395125B (en) 2007-06-06
EP1562573A1 (en) 2005-08-17
DK1562573T3 (da) 2006-08-21
ES2257589T3 (es) 2006-08-01
FIU20020500U0 (fi) 2002-12-16
HUP0500832A3 (en) 2009-12-28
DE60210828T2 (de) 2006-10-19

Similar Documents

Publication Publication Date Title
NO20052860L (no) Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme
AU594392B2 (en) Pharmaceutical preparation
ATE380022T1 (de) Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
WO2004022031A3 (en) Stable probiotic microsphere compositions and their methods of preparation
EP3154523B1 (en) Formulation for oral administration containing mesalazine
CA2382098C (en) Sustained-release, oral pharmaceutical forms of administration
US4367217A (en) Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
CA1205384A (en) Delayed-release form of bromhexine and process for the preparation thereof
US5175003A (en) Dual mechanism controlled release system for drug dosage forms
DE60036874D1 (de) Pellet formulierung mit gesteuerter freisetzung
CA2611114A1 (en) An entacapone-containing oral dosage form
LV12602A (en) Enteric coated pharmaceutical composition and method of manufacturing
YU57692A (sh) Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
NO792335L (no) Legemiddel-retardform med uopploeselige, poroese diffusjonsovertrekk
JP2007507553A5 (no)
SK280487B6 (sk) Poťahovacie a spojivové látky na liekové formy, ic
ATE243026T1 (de) Bupropion-darreichungsform mit kontrollierter freisetzung
JP2008507483A (ja) 安定な作用物質放出プロフィールを有するコーティングされた剤形の製造方法
SU1218919A3 (ru) Способ получени цефалексина продленного действи дл перорального применени
NZ240853A (en) Phased-release oral dosage form comprising an histamine receptor antagonist in a polymer matrix
ATE344659T1 (de) Tablettenzubereitung mit verlängerter freisetzung von venlafaxin
JPS58109413A (ja) 耐衝撃性腸溶錠
SU1478993A3 (ru) Способ получени микрогранул
RU2018100755A (ru) Комбинированный препарат мозаприда и рабепразола
Chhipa et al. Formulation optimization of sustained release pellets of itopride hydrochloride using different polymers

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application